| Literature DB >> 28630872 |
Katarzyna Podgórska1, Arkadiusz Derkacz1,2, Ewa Szahidewicz-Krupska1,2, Jakub Jasiczek1,2, Piotr Dobrowolski3, Aneta Radziwon-Balicka4, Robert Skomro5, Andrzej Szuba1, Grzegorz Mazur2, Adrian Doroszko1,2.
Abstract
The aim of the study was to assess the impact of regular professional sports activity on the endothelial and platelet function in young men. The studied group were 79 young men (18-40 y, 25 athletes and 54 without any regular physical activity). The nitric oxide (NO) metabolic pathway intermediates, oxidative stress markers, mediators of inflammation, and platelet aggregation were measured. Flow mediated dilation (FMD) was studied before and after intravenous 16,0 g L-arginine infusion, which was repeated after oral administration of acetylsalicylic acid (ASA-75 mg/day) for 4 days. Both groups had similar demographic characteristics. In the athletes, there was significantly higher hsCRP level, better serum lipid profile, and lower pulse pressure. Greater baseline FMD in athletes and in response to L-arginine disappeared following ASA treatment. There were no differences in the levels of the NO pathway metabolites. The control group was characterized by higher PAI-1 following ASA treatment and sICAM-1 both at baseline and after ASA, but no differences in MDA and 6-keto-PGF-1 alpha and platelet aggregation were noted. Regular professional physical activity modulates endothelial but not platelet function and may thus exert an effect on overall cardiovascular risk.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28630872 PMCID: PMC5467294 DOI: 10.1155/2017/8715909
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1(a) A scheme of the study protocol. (b) Schematic subjects' categorization.
Baseline demographic characteristics of analyzed groups.
| Parameter | Athletes | Control |
|
|---|---|---|---|
| Age [years] | 23,52 ± 0,37 | 24,58 ± 0,55 | 0,07 |
| HR [bpm] | 69,00 ± 2,43 | 72,08 ± 1,94 | 0,21 |
| SBP [mmHg] | 122,91 ± 1,94 | 126,78 ± 2,57 | 0,07 |
| DBP [mmHg] | 81,45 ± 1,84 | 81,21 ± 1,89 | 1,00 |
| MAP [mmHg] | 95,27 ± 1,65 | 96,12 ± 1,96 | 0,55 |
| PP [mmHg] | 41,45 ± 1,89 | 46,40 ± 2,03 | 0,04 |
| BMI [kg/m2] | 25,82 ± 0,58 | 26,41 ± 0,66 | 0,57 |
| WHR [1] | 0,95 ± 0,0 | 0,938 ± 0,01 | 0,29 |
| TCh [mg/dl] | 161,04 ± 5,93 | 182,25 ± 6,95 | 0,01 |
| HDL [mg/dl] | 55,7 ± 2,83 | 48,73 ± 1,58 | 0,03 |
| LDL [mg/dl] | 82,28 ± 5,25 | 105,2 ± 5,70 | 0,006 |
| TG [mg/dl] | 112,36 ± 14,54 | 147,85 ± 12,46 | 0,07 |
| hsCRP [mg/l] | 3,52 ± 0,23 | 2,40 ± 0,37 | 0,003 |
| Glucose [mg/dl] | 84,66 ± 2,17 | 84,53 ± 1,81 | 0,68 |
| Creatinine [mg/dl] | 0,96 ± 0,02 | 0,96 ± 0,02 | 0,70 |
| eGFR [ml/(min × 1,73 m2)] | 147,48 ± 4,98 | 130,44 ± 8,19 | 0,07 |
| Uric acid [mg/dl] | 6,15 ± 0,26 | 6,18 ± 0,23 | 0,98 |
| K+ [mmol/l] | 3,98 ± 0,05 | 5,03 ± 0,05 | 0,10 |
| Na+ [mmol/l] | 142,65 ± 0,22 | 141,42 ± 0,32 | 0,02 |
| Urea [mg/dl] | 36,62 ± 1,41 | 31,4 ± 1,35 | 0,003 |
| C-R PWV [m/s] | 9,61 ± 0,36 | 10,69 ± 0,34 | 0,04 |
| C-F PWV [m/s] | 9,51 ± 0,24 | 9,90 ± 0,32 | 0,67 |
| C-D PWV [m/s] | 8,15 ± 0,19 | 8,91 ± 0,24 | 0,01 |
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean blood pressure; PP: pulse pressure; BMI: body mass index; WHR: waist-hips ratio; TCh: total cholesterol; HDL: high-density lipoproteins; LDL: low-density lipoproteins; TG: triglycerides; eGFR: estimated glomerular filtration rate; hsCRP: high-sensitivity C-reactive protein; C-R PWV: carotid-radial pulse wave velocity, C-F PWV: carotid-femoral pulse wave velocity; C-D PWV: carotid-dorsal pedis pulse wave velocity.
Flow mediated dilatation (FMD) and markers of the nitric oxide metabolic pathway in both groups.
| Parameter | Athletes | Control |
|
|---|---|---|---|
| FMD [%] | |||
| Baseline | 9,62 ± 0,70 | 8,05 ± 0,59 | 0,049 |
| Baseline + L-Arg | 11,74 ± 0,60 | 8,93 ± 0,67 | 0,01 |
|
|
| ||
|
| |||
| FMD [%] | |||
| ASA | 9,20 ± 0,70 | 7,77 ± 0,82 | ns |
| ASA + L-Arg | 8,94 ± 0,56 | 7,86 ± 0,85 | ns |
|
|
| ||
|
| |||
| L-arginine [ | |||
| Baseline | 60,33 ± 3,83 | 65,07 ± 2,47 | ns |
| After ASA | 68,37 ± 5,37 | 63,73 ± 2,73 | ns |
|
|
| ||
|
| |||
| ADMA [ | |||
| Baseline | 0,42 ± 0,016 | 0,42 ± 0,01 | ns |
| After ASA | 0,42 ± 0,02 | 0,41 ± 0,01 | ns |
|
|
| ||
|
| |||
| SDMA [ | |||
| Baseline | 0,46 ± 0,016 | 0,47 ± 0,02 | ns |
| After ASA | 0,47 ± 0,018 | 0,51 ± 0,03 | ns |
|
|
| ||
FMD: flow mediated dilation, ADMA: asymmetric dimethylarginine, L-Arg: L-arginine, ASA: acetylsalicylic acid, and SDMA: symmetric dimethylarginine.
Figure 2(a) Comparison of the oxidative stress markers in the subgroups at particular steps of the study protocol. (b) Comparison of the prostanoids levels in the subgroups at particular steps of the study protocol. (c) Comparison of the endothelial activation markers in the subgroups at particular steps of the study protocol. GSH/GSSG: thiol index, the reduced to oxidized glutathione ratio, MDA: malondialdehyde (lipid peroxidation marker), TXB2: thromboxane B2, 6-keto-PGF-1 alpha: 6-keto-prostaglandin F-1 alpha (a metabolite of prostacyclin, PGI2), PAI-1: plasminogen activator inhibitor-1, sVCAM-1: soluble vascular cell adhesion molecule-1, sICAM-1: soluble intercellular adhesion molecule-1, and VEGF: vascular endothelial growth factor. p < 0,05 versus control. #p < 0,05 versus the same group at baseline.
Platelet aggregation in both groups.
| Parameter | Athletes | Control |
|
|---|---|---|---|
| Arachidonic acid-induced aggregation [AU] | |||
| Baseline | 151,81 ± 7,72 | 147,11 ± 4,08 | ns |
| After ASA | 90,8 ± 11,47 | 73,37 ± 5,69 | ns |
|
|
| ||
|
| |||
| ADP-induced aggregation [AU] | |||
| Baseline | 122,73 ± 7,39 | 118,39 ± 4,07 | ns |
| After ASA | 114,88 ± 8,48 | 106,63 ± 5,79 | ns |
|
|
| ||